Hormone Replacement Therapy (HRT) Should Be First-Line Treatment for Mental Health Symptoms During Menopause
For women experiencing mood disturbance, anxiety, or depression during perimenopause and early menopause (under age 60 or within 10 years of menopause onset), menopausal hormone therapy (MHT) is the recommended first-line treatment 1, 2. This recommendation is based on the profound hormonal modulation of key neurotransmitter systems including serotonin, GABA, and allopregnanolone that occurs during this transition 2.
Treatment Algorithm
Step 1: Assess Timing and Candidacy for HRT
- Initiate HRT if the patient is:
- Under age 60, OR
- Within 10 years of menopause onset
- Experiencing vasomotor symptoms (hot flushes) AND/OR mood disturbance
- No contraindications (screen for cardiovascular disease and breast cancer risk) 1
The Endocrine Society guideline explicitly states that benefits exceed risks for the majority of symptomatic postmenopausal women meeting these criteria 1. Recent evidence emphasizes that NICE guidance recommends HRT as first-line treatment specifically for perimenopausal mood disturbance 2.
Step 2: Add Psychological Interventions Alongside HRT
Cognitive Behavioral Therapy (CBT) should be offered concurrently with HRT, delivered in 4-6 sessions targeting:
- Vasomotor symptoms
- Sleep problems
- Stress and low mood 3
CBT has been consistently effective across multiple delivery formats (group, self-help, online) and is recommended by the North American Menopause Society for VMS treatment and by NICE for anxiety and depression during menopause 3.
Mindfulness-based interventions provide additional benefit, with recent high-quality RCT evidence showing significant improvements in:
- Anxiety (effect size d = 1.221)
- Depression (d = 0.880)
- Stress (d = 1.030)
- Overall quality of life across all domains 4
Step 3: Non-Hormonal Pharmacological Options
If HRT is contraindicated or declined, use these evidence-based alternatives:
- Neurokinin 3B antagonists (fezolinetant)
- SSRIs/SNRIs (selective serotonin/norepinephrine reuptake inhibitors)
- Gabapentin 5
These are specifically recommended for vasomotor symptoms and have secondary benefits for mood 1, 5.
Step 4: Lifestyle and Biopsychosocial Support
All women should receive individualized menopause management through a biopsychosocial approach that includes:
Critical Clinical Pitfalls
Do not use antidepressants as first-line treatment for perimenopausal mood symptoms without considering HRT first 2. The evidence shows that many women are left unsupported due to clinician lack of awareness and confidence in prescribing HRT, despite clear guideline recommendations 2.
Recognize that perimenopause (not just postmenopause) is when mental health challenges are most acute 2. Women can spend up to 12% of their lives in perimenopause, and this is when hormonal fluctuations cause the most severe symptoms, including hormonally-related depression and suicidality (evidenced by peak suicide rates in midlife women) 2.
Do not prescribe HRT for prevention of dementia, coronary heart disease, or breast cancer - current evidence does not support these indications 1.
Strength of Evidence
The guideline evidence 1 provides the framework, with the most recent research 2 from 2026 strongly reinforcing HRT as first-line for mental health symptoms. The mindfulness RCT 4 from 2025 provides the highest quality evidence for adjunctive psychological intervention with large effect sizes. The systematic review of menopause guidelines 5 confirms consistency across high-quality CPGs that MHT is indicated for menopause-associated mood disturbance, while CBT evidence 3 demonstrates robust effectiveness across multiple trials and delivery formats.